Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11278
Title: Low testosterone in men with type 2 diabetes: significance and treatment.
Authors: Grossmann, Mathis
Affiliation: mathisg@unimelb.edu.au
Department of Medicine, Austin Health/Northern Health, University of Melbourne, Heidelberg, VIC 3084, Australia
Issue Date: 6-Jun-2011
Citation: The Journal of Clinical Endocrinology and Metabolism 2011; 96(8): 2341-53
Abstract: The relationship between testosterone and diabetes in men is an important issue, given that one third of U.S. men aged 65 yr or older have diabetes, with a similar percentage having low testosterone levels.The medical literature from 1970 to March 2011 was reviewed for key articles.In population-based studies, low testosterone is commonly associated with type 2 diabetes and the metabolic syndrome, and it identifies men with an adverse metabolic profile. The difference in testosterone levels between men with diabetes compared to men without diabetes is moderate and comparable in magnitude to the effects of other chronic diseases, suggesting that low testosterone may be a marker of poor health. Although the inverse association of testosterone with diabetes is partially mediated by SHBG, low testosterone is linked to diabetes via a bidirectional relationship with visceral fat, muscle, and possibly bone. There is consistent evidence from randomized trials that testosterone therapy alters body composition in a metabolically favorable manner, but changes are modest and have not consistently translated into reductions in insulin resistance or improvements in glucose metabolism.The key response to the aging, overweight man with type 2 diabetes and subnormal testosterone levels should be implementation of lifestyle measures such as weight loss and exercise, which, if successful, raise testosterone and provide multiple health benefits. Although approved therapy for diabetes should be used, testosterone therapy should not be given to such men until benefits and risks are clarified by adequately powered clinical trials.
Internal ID Number: 21646372
URI: http://ahro.austin.org.au/austinjspui/handle/1/11278
DOI: 10.1210/jc.2011-0118
URL: http://www.ncbi.nlm.nih.gov/pubmed/21646372
Type: Journal Article
Subjects: Androgens.blood.deficiency.therapeutic use
Diabetes Mellitus, Type 2.complications
Humans
Hypogonadism.blood.drug therapy.etiology
Male
Testosterone.blood.deficiency.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.